Laura Murillo

Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility

Patrick Sulem, Daníel F. Guðbjartsson, Thórarinn Blöndal et al. · Nature Genetics · 2009 · 351 citations · Full text

Life Sciences, Genetics, Oncology +16

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski et al. · Clinical Cancer Research · 2023 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Bárbara Adamo, Meritxell Bellet, Laia Paré et al. · Breast Cancer Research · 2019 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · European Journal of Cancer · 2022 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17